Advertisement
Clinical Therapeutics
Advanced searchSave search
Rapid Communication| Volume 31, ISSUE 9, P1966-1976, September 2009

Effect of agalsidase alfa replacement therapy on fabry disease—related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis

DOI:https://doi.org/10.1016/j.clinthera.2009.09.008
Effect of agalsidase alfa replacement therapy on fabry disease—related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis
Previous ArticlePrediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt: Secondary analysis of two parallel, 10-week, randomized, double-blind, placebo-controlled clinical trials of 21-mg nicotine patch in adult smokers
Next ArticleTolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: A retrospective chart review
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Background: Fabry disease is an X-linked disease caused by a deficiency in the activity of the lysosomal enzyme α-galactosidase A. Affected individuals typically develop left ventricular hypertrophy (LVH) among other pathologies.
      Objective: The purpose of the present study was to investigate the effect of ≥12 months of enzyme replacement therapy (ERT) with agalsidase alfa on LV mass (LVM) in men and women with Fabry disease.
      Methods: This was a retrospective, blinded, pooled analysis of data from several studies assessing the effect of ERT with agalsidase alfa on LVM in patients with Fabry disease with baseline LVH. Men and women aged ≥18 years with a confirmed diagnosis of Fabry disease who had received ≥36 months of ERT with agalsidase alfa were eligible, provided they had a baseline echocardiogram and a follow-up echocardiogram at 12 and/or 36 months. Data from 4 studies were included in the present analysis. LVM was normalized to height (in meters) to the 2.7 power (LVM/h = LVM/m2.7).
      Results: In total, 45 adult patients (34 men and 11 women) with a confirmed diagnosis of Fabry disease and serial echocardiograms obtained at baseline and after 12 and/or 36 months of treatment were included. The mean (SD) age of this cohort was 39.8 (10.4) years (range, 18.9–67.2 years), and the mean weight was 72.5 (13.4) kg (range, 46.7–102.9 kg). Forty-two patients were white, 2 were Hispanic, and 1 was classified as other. At baseline, 14 patients had LVH (mean LVM/h = 55.4 [5.7] g/m2.7). After 12 months of ERT with agalsidase alfa, LVM/h decreased significantly by 9.2 (7.9) g/m2.7 in 9 patients (P = 0.008), and after 36 months, LVM/h decreased significantly by 5.1 (7.5) g/m2.7 in 10 patients (P = 0.037). In patients without baseline LVH (n = 31), a significant increase in LVM/h was observed after 12 months of treatment (3.6 [5.7] g/m2.7; P = 0.002). After 36 months of treatment, however, there was no significant change from baseline in 10 patients (2.1 [7.9] g/m2.7; P = NS).
      Conclusion: Treatment with agalsidase alfa for 12 or 36 months was associated with reduced LVM in these patients with Fabry disease with baseline LVH, and it appeared to stabilize LVM in these patients without baseline LVH.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Brady RO
        • Gal AE
        • Bradley RM
        • et al.
        Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.
        N Engl J Med. 1967; 276: 1163-1167
        • Meikle PJ
        • Hopwood JJ
        • Clague AE
        • Carey WF
        Prevalence of lysosomal storage disorders.
        JAMA. 1999; 281: 249-254
        • MacDermot KD
        • Holmes A
        • Miners AH
        Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males.
        J Med Genet. 2001; 38: 750-760
        • MacDermot KD
        • Holmes A
        • Miners AH
        Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.
        J Med Genet. 2001; 38: 769-775
        • Linhart A
        • Kampmann C
        • Zamorano JL
        • et al.
        • European FOS Investigators
        Cardiac manifestations of Anderson-Fabry disease: Results from the international Fabry Outcome Survey.
        Eur Heart J. 2007; 28: 1228-1235
        • Shah JS
        • Elliott PM
        Fabry disease and the heart: An overview of the natural history and the effect of enzyme replacement therapy.
        Acta Paediatr Suppl. 2005; 94 (discussion): 11-14
        • Shah JS
        • Elliott PM
        Fabry disease and the heart: An overview of the natural history and the effect of enzyme replacement therapy.
        Acta Paediatr Suppl. 2005; 94: 9-10

      8. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy [published online ahead of print February 9, 2009]. Nephrol Dial Transplant.

        • Kampmann C
        • Wiethoff CM
        • Perrot A
        • et al.
        The heart in Anderson Fabry disease.
        Z Kardiol. 2002; 91: 786-795
        • Hasegawa H
        • Takano H
        • Shindo S
        • et al.
        Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease.
        Circulation. 2006; 113: e720-e721
        • Funabashi N
        • Toyozaki T
        • Matsumoto Y
        • et al.
        Images in cardiovascular medicine. Myocardial fibrosis in Fabry disease demonstrated by multislice computed tomography: Comparison with biopsy findings.
        Circulation. 2003; 107: 2519-2520
        • Linhart A
        • Palecek T
        • Bultas J
        • et al.
        New insights in cardiac structural changes in patients with Fabry's disease.
        Am Heart J. 2000; 139: 1101-1108
        • Goldman ME
        • Cantor R
        • Schwartz MF
        • et al.
        Echocardiographic abnormalities and disease severity in Fabry's disease.
        J Am Coll Cardiol. 1986; 7: 1157-1161
        • Kampmann C
        • Baehner F
        • Whybra C
        • et al.
        Cardiac manifestations of Anderson-Fabry disease in heterozygous females.
        J Am Coll Cardiol. 2002; 40: 1668-1674
        • Linhart A
        Treatment of Anderson-Fabry disease.
        Heart. 2008; 94: 138-139
        • Kampmann C
        • Linhart A
        • Baehner F
        • et al.
        Onset and progression of the Anderson-Fabry disease related cardiomyopathy.
        Int J Cardiol. 2008; 130: 367-373
        • Shah JS
        • Lee P
        • Hughes D
        • et al.
        The natural history of left ventricular systolic function in Anderson-Fabry disease.
        Heart. 2005; 91: 533-534
        • Pochis WT
        • Litzow JT
        • King BG
        • Kenny D
        Electrophysiologic findings in Fabry's disease with a short PR interval.
        Am J Cardiol. 1994; 74: 203-204
        • Shah JS
        • Hughes DA
        • Sachdev B
        • et al.
        Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.
        Am J Cardiol. 2005; 96: 842-846
        • Schiffmann R
        • Kopp JB
        • Austin III, HA
        • et al.
        Enzyme replacement therapy in Fabry disease: A randomized controlled trial.
        JAMA. 2001; 285: 2743-2749
        • Eng CM
        • Guffon N
        • Wilcox WR
        • et al.
        • International Collaborative Fabry Disease Study Group
        Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease.
        N Engl J Med. 2001; 345: 9-16
        • Banikazemi M
        • Bultas J
        • Waldek S
        • et al.
        • Fabry Disease Clinical Trial Study Group
        Agalsidase-beta therapy for advanced Fabry disease: A randomized trial.
        Ann Intern Med. 2007; 146: 77-86
        • Schiffmann R
        • Ries M
        • Timmons M
        • et al.
        Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting.
        Nephrol Dial Transplant. 2006; 21: 345-354
        • Germain DP
        • Waldek S
        • Banikazemi M
        • et al.
        Sustained, long-term renalstabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
        J Am Soc Nephrol. 2007; 18: 1547-1557
        • Hughes DA
        • Elliott PM
        • Shah J
        • et al.
        Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebocontrolled clinical trial of agalsidasealfa.
        Heart. 2008; 94: 153-158
        • Ries M
        • Clarke JT
        • Whybra C
        • et al.
        Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
        Pediatrics. 2006; 118: 924-932
        • Weidemann F
        • Breunig F
        • Beer M
        • et al.
        Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study.
        Circulation. 2003; 108: 1299-1301
        • Spinelli L
        • Pisani A
        • Sabbatini M
        • et al.
        Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.
        Clin Genet. 2004; 66: 158-165
        • Weidemann F
        • Niemann M
        • Breunig F
        • et al.
        Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: Evidence for a better outcome with early treatment.
        Circulation. 2009; 119: 524-529
        • Pisani A
        • Spinelli L
        • Sabbatini M
        • et al.
        Enzyme replacement therapy in Fabry disease patients undergoing dialysis: Effects on quality of life and organ involvement.
        Am J Kidney Dis. 2005; 46: 120-127
        • Elliott PM
        • Kindler H
        • Shah JS
        • et al.
        Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A.
        Heart. 2006; 92: 357-360
        • Kalliokoski RJ
        • Kantola I
        • Kalliokoski KK
        • et al.
        The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease.
        J Inherit Metab Dis. 2006; 29: 112-118
        • Whybra C
        • Mieback E
        • Mengel E
        • et al.
        A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease.
        Genet Med. 2009; 11: 441-449
        • Mehta A
        • Ricci R
        • Widmer U
        • et al.
        Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.
        Eur J Clin Invest. 2004; 34: 236-242
        • Beck M
        • Ricci R
        • Widmer U
        • et al.
        Fabry disease: Overall effects of agalsidase alfa treatment.
        Eur J Clin Invest. 2004; 34: 838-844
        • Sahn DJ
        • DeMaria A
        • Kisslo J
        • Weyman A
        Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements.
        Circulation. 1978; 58: 1072-1083
        • Schiller NB
        • Shah PM
        • Crawford M
        • et al.
        • American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms
        Recommendations for quantitation of the left ventricle by two-dimensional echocardiography.
        J Am Soc Echocardiogr. 1989; 2: 358-367
        • Devereux RB
        Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods.
        Hypertension. 1987; 9: II19-II26
        • de Simone G
        • Daniels SR
        • Devereux RB
        • et al.
        Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight.
        J Am Coll Cardiol. 1992; 20: 1251-1260
        • Breunig F
        • Weidemann F
        • Strotmann J
        • et al.
        Clinical benefit of enzyme replacement therapy in Fabry disease.
        Kidney Int. 2006; 69: 1216-1221
        • Beer M
        • Weidemann F
        • Breunig F
        • et al.
        Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.
        Am J Cardiol. 2006; 97: 1515-1518
        • Vedder AC
        • Breunig F
        • Donker-Koopman WE
        • et al.
        Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3.
        Mol Genet Metab. 2008; 94: 319-325
        • Elleder M
        • Bradová V
        • Smíd F
        • et al.
        Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy.
        Virchows Arch A Pathol Anat Histopathol. 1990; 417: 449-455
        • Sadick N
        • Thomas L
        Cardiovascular manifestations in Fabry disease: A clinical and echocardiographic study.
        Heart Lung Circ. 2007; 16: 200-206
        • Uchino M
        • Uyama E
        • Kawano H
        • et al.
        A histochemical and electron microscopic study of skeletal and cardiac muscle from a Fabry disease patient and carrier.
        Acta Neuropathol. 1995; 90: 334-338
        • Demuth K
        • Germain DP
        Endothelial markers and homocysteine in patients with classic Fabry disease.
        Acta Paediatr Suppl. 2002; 91: 57-61

      Article info

      Publication history

      Accepted: June 17, 2009

      Identification

      DOI: https://doi.org/10.1016/j.clinthera.2009.09.008

      Copyright

      © 2009 Excerpta Medica Inc. All rights reserved. Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX